THE Childrens Hospital Kidney Ctr. is a medicare approved dialysis facility center in Aurora, Colorado and it has 9 dialysis stations. It is located in Adams county at 13123 E 16th Ave #328, Aurora, CO, 80045. You can reach out to the office of THE Childrens Hospital Kidney Ctr. at (720) 777-6263. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. THE Childrens Hospital Kidney Ctr. has the following ownership type - Non-Profit. It was first certified by medicare in February, 1992. The medicare id for this facility is 063301 and it accepts patients under medicare ESRD program.
Name | THE Childrens Hospital Kidney Ctr. |
---|---|
Location | 13123 E 16th Ave #328, Aurora, Colorado |
No. of Dialysis Stations | 9 |
Medicare ID | 063301 |
Managed By | Independent |
Ownership Type | Non-Profit |
Late Shifts | No |
13123 E 16th Ave #328, Aurora, Colorado, 80045 | |
(720) 777-6263 | |
Not Available |
News Archive
A clinical decision model which uses MR spectroscopy to help physicians differentiate between recurrent tumors and changes in the brain tissue due to radiation treatments, may help patients avoid invasive procedures and treatments, according to a study performed at the University of Michigan Health System in Ann Arbor, MI.
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of "atypical antipsychotic drugs."
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.
Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.
› Verified 5 days ago
NPI Number | 1720243348 |
Organization Name | The Children's Hospital Association |
Doing Business As | Children's Hospital Colorado |
Address | 13123 E 16th Ave Aurora, Colorado, 80045 |
Phone Number | (720) 777-1234 |
News Archive
A clinical decision model which uses MR spectroscopy to help physicians differentiate between recurrent tumors and changes in the brain tissue due to radiation treatments, may help patients avoid invasive procedures and treatments, according to a study performed at the University of Michigan Health System in Ann Arbor, MI.
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of "atypical antipsychotic drugs."
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.
Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.
› Verified 5 days ago
Dialysis patients with Hemoglobin data | 1 |
News Archive
A clinical decision model which uses MR spectroscopy to help physicians differentiate between recurrent tumors and changes in the brain tissue due to radiation treatments, may help patients avoid invasive procedures and treatments, according to a study performed at the University of Michigan Health System in Ann Arbor, MI.
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of "atypical antipsychotic drugs."
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.
Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
Adult patients getting regular hemodialysis at the center | 2 |
Adult patient months included in Kt/V greater than or equal to 1.2 | 8 |
Pediatic patients getting regular hemodialysis at the center | 6 |
Pediatric patient months included in in Kt/V greater than or eqaul to 1.2 | 31 |
News Archive
A clinical decision model which uses MR spectroscopy to help physicians differentiate between recurrent tumors and changes in the brain tissue due to radiation treatments, may help patients avoid invasive procedures and treatments, according to a study performed at the University of Michigan Health System in Ann Arbor, MI.
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of "atypical antipsychotic drugs."
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.
Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.
› Verified 5 days ago
Adult patients getting regular peritoneal dialysis at the center | 1 |
Adult patient months included in Kt/V greater than or equal to 1.7 | 3 |
Pediatric patients getting regular peritoneal dialysis at the centre | 15 |
Pediatric patient months included in Kt/V greater than or equal to 1.7 | 66 |
Percentage of pediatric patients getting regular peritoneal dialysis at the center | 52 |
News Archive
A clinical decision model which uses MR spectroscopy to help physicians differentiate between recurrent tumors and changes in the brain tissue due to radiation treatments, may help patients avoid invasive procedures and treatments, according to a study performed at the University of Michigan Health System in Ann Arbor, MI.
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of "atypical antipsychotic drugs."
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.
Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at THE Childrens Hospital Kidney Ctr. with elevated calcium levels.
Patients with hypercalcemia | 2 |
Hypercalcemia patient months | 12 |
Patients with Serumphosphor | 2 |
News Archive
A clinical decision model which uses MR spectroscopy to help physicians differentiate between recurrent tumors and changes in the brain tissue due to radiation treatments, may help patients avoid invasive procedures and treatments, according to a study performed at the University of Michigan Health System in Ann Arbor, MI.
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of "atypical antipsychotic drugs."
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.
Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
Patients in facility's Hospitalization Summary | 3 |
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether THE Childrens Hospital Kidney Ctr.'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
Patients in facility's Transfusion Summary | 2 |
News Archive
A clinical decision model which uses MR spectroscopy to help physicians differentiate between recurrent tumors and changes in the brain tissue due to radiation treatments, may help patients avoid invasive procedures and treatments, according to a study performed at the University of Michigan Health System in Ann Arbor, MI.
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of "atypical antipsychotic drugs."
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.
Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.
› Verified 5 days ago
The rate of mortality show you whether patients who were being treated regularly at THE Childrens Hospital Kidney Ctr. lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
Patients in facility's Survival Summary | 128 |
Mortality Rate in facility | 5.7 (As Expected) |
Mortality Rate: Upper Confidence Limit | 31.9 |
Mortality Rate: Lower Confidence Limit | .1 |
News Archive
A clinical decision model which uses MR spectroscopy to help physicians differentiate between recurrent tumors and changes in the brain tissue due to radiation treatments, may help patients avoid invasive procedures and treatments, according to a study performed at the University of Michigan Health System in Ann Arbor, MI.
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of "atypical antipsychotic drugs."
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.
Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.
› Verified 5 days ago
University Of Co Hospital - Home Dialysis Location: 12605 E. 16th Ave, Aurora, Colorado, 80045 Phone: (720) 848-3102 |
Aurora Dialysis (DVA) Location: 1411 S Potomac St Ste 100, Aurora, Colorado, 80012 Phone: (303) 368-1911 |
News Archive
A clinical decision model which uses MR spectroscopy to help physicians differentiate between recurrent tumors and changes in the brain tissue due to radiation treatments, may help patients avoid invasive procedures and treatments, according to a study performed at the University of Michigan Health System in Ann Arbor, MI.
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of "atypical antipsychotic drugs."
It has so far not been proven that the long-acting insulin analogues (LAIAs) insulin detemir (trade name: Levemir) and insulin glargine (trade name: Lantus), which are approved for the treatment of type 1 diabetes, offer patients an additional benefit versus long-acting human insulin. This applies to adults as well as to children and adolescents. This is the result of the final report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 19 April 2010.
Findings from a study carried out in mice suggest that an intermittent dosing strategy may be the answer to combating lethal tumor resistance to the BRAF inhibitor vemurafenib, in patients with late-stage BRAF-mutated melanoma.
› Verified 5 days ago